Syndax Announces Participation in February Investor Conferences

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies [2] - The company has an FDA-approved pipeline that includes Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) [2] - Syndax is committed to advancing cancer care through ongoing clinical trials [2] Upcoming Events - Syndax's CEO and management team will participate in the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET [4] - The company will also be featured in Citi's 2025 Virtual Oncology Leadership Summit on February 19, 2025, at 9:00 a.m. ET [4] - Live webcasts of these events will be available on the company's website [1]